Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The Role of Hypoxia as a Selective Pressure for TP53 Mutations

27. januar 2020 oppdatert av: Nandita deSouza, Institute of Cancer Research, United Kingdom

The study aims to develop scans that tell the investigators about the oxygen content of tumours using Magnetic Resonance Imaging (MRI) and seeing whether regions of low oxygen content are related to mutations in cancer genes such as TP53. MRI is a method of obtaining pictures of inside of the body that shows the appearance and structure of soft tissues.

To get the information about the oxygen content of tumours, MRI is carried out while breathing 100% oxygen. The variation of oxygen supply to different regions of the tumour will help the investigators to predict tumour behavior and tumour response to treatment.

Studieoversikt

Status

Avsluttet

Forhold

Detaljert beskrivelse

Cancer tissue harbours a multitude of genetic alterations, and it is well-established that when certain key alterations develop, they are powerful determinants of tumour behaviour (growth rate, potential to spread). One of the most sinister and well-recognized alterations is in a gene called TP53. Another feature of tumours that results in resistance to treatment and poor outcome is a low oxygen level within tumour tissue. However, whether alterations in TP53 are driven by low oxygen levels is not established.

Endometrial cancer is a good model to study the relationship between low tumour oxygen levels and alterations in TP53 within tumour. Firstly, it is a common gynaecological malignancy, (9,300 new cases annually in the UK) with two recognized types based on the appearance and behaviour of the tumour. In type I (endometrioid and mucinous carcinomas), alterations in TP53 are uncommon (15%), while in type II (serous and clear cell carcinomas) they are common (88%). In-line with this, the survival of patients with Type 2 cancer is worse. Secondly, endometrial cancer is routinely assessed at diagnosis using Magnetic Resonance Imaging. This non-invasive scanning technique can be manipulated to derive additional information about the oxygen status of the whole tumour and regions within it. Finally, the primary management of endometrial cancer is surgical and involves hysterectomy. This means it is possible to obtain fresh tumour tissue at the time of surgery from regions that have been identified on imaging as having low vs.high levels of oxygen and to establish their TP53 status. In this study, therefore, the investigator will establish the regional oxygen distribution within endometrial cancers at diagnosis, and relate them to the alterations in TP53 from fresh tissue samples from selected regions using gene sequencing. Understanding how highly deleterious mutations arise in cancer might provide new avenues for intervention and control.

Studietype

Observasjonsmessig

Registrering (Faktiske)

5

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • Surrey
      • Sutton, Surrey, Storbritannia, SM2 5PT
        • The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Hunn

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

Participants scheduled to have hysterectomy at the cancer centre

Beskrivelse

Inclusion Criteria:

  1. ≥18 years of age on the day of signing the informed consent.
  2. Histologically confirmed endometroid or serous endometrial cancer.
  3. Scheduled to have hysterectomy at the cancer centre
  4. Identifiable tumour mass on staging MRI.
  5. Voluntarily agreed to participate by giving written informed consent.

Exclusion Criteria:

  1. Life expectancy of < 6 months.
  2. Ferromagnetic implants, contraindicating MRI
  3. Claustrophobia so unable to tolerate MRI
  4. Unable to lie flat
  5. Ascites sufficient to prevent patient being fitted in the scanner bore
  6. Histology unlikely to show variation in TP53 status, or heavily calcified disease.
  7. Radiotherapy to the abdomen or pelvis within 6 months of the screening visit.
  8. Unresolved bowel obstruction.
  9. Currently participating or has participated in a study with an investigational compound or device within 30 days of the start of treatment.
  10. History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with patient's participation for the full duration of the study, or is not in the best interest of the patient to participate.
  11. Unlikely to comply with the requirements of the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Endometriod
Type I (endometrioid and mucinous carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.
Serous
Type II (serous and clear cell carcinomas) - Magnetic Resonance Imaging (MRI) with 100% Oxygen.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Establish distinctive patterns of distribution and expression of mutant TP53 between tumour regions with differing levels of oxygenation (as measured by R2*on MRI).
Tidsramme: Duration of study (24 months)
Determined at post surgery histology
Duration of study (24 months)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The reproducibility of the R2* measurement, assessed by comparing 2 R2* scans per person
Tidsramme: 6 months
comparison of image data at conclusion of MRI scan
6 months
Establish the range of intratumoral heterogeneity of the R2* measurement within individual tumours
Tidsramme: 6 months
comparison of image data at conclusion of MRI scan
6 months

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Nandita deSouza, The Institution of Cancer Research & The Royal Marsden NHS Foundation Trust

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

6. februar 2018

Primær fullføring (Faktiske)

19. juni 2018

Studiet fullført (Faktiske)

30. juli 2019

Datoer for studieregistrering

Først innsendt

12. februar 2018

Først innsendt som oppfylte QC-kriteriene

8. mars 2018

Først lagt ut (Faktiske)

15. mars 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

29. januar 2020

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. januar 2020

Sist bekreftet

1. januar 2020

Mer informasjon

Begreper knyttet til denne studien

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere